Research progress of induced pluripotent stem cells in cell models of hereditary cardiomyopathy

doi:10.3877/cma.j.issn.2095-1221.2023.05.009

Abstract

Abstract:

Hereditary cardiomyopathy is a group of diseases characterized by abnormalities in myocardial structure and function due to genetic mutations, which leads to heart failure, arrhythmias and even sudden death. The discovery of induced pluripotent stem cells has promoted the in vitro study of a variety of human diseases. The cardiomyocytes obtained by induction provide important disease cell models for the study of the mechanism of hereditary cardiomyopathies and drug development and have been widely used in basic research. This article summarizs the types, clinical manifestations and common pathogenic mutated genes of hereditary cardiomyopathy, used induced pluripotent stem cell-derived cardiomyocytes as in vitro models to simulate the phenotypes of various types of hereditary cardiomyopathy, and further explores the related pathogenic mechanisms caused by gene mutations, providing sufficient seed cells for the genetic, molecular and cytological pathogenesis of hereditary cardiomyopathy. It also provides a valuable research model for drug development of diseases.

Key words: Hereditary, Cardiomyopathy, Induced pluripotent stem cells, Cell model

Bingbing Xie, Manting Xie, Qiuling Xiang. Research progress of induced pluripotent stem cells in cell models of hereditary cardiomyopathy[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(05): 315-320.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2023.05.009

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2023/V13/I05/315

Figures/Tables 2

References 55

1	Fadl SA, Revels JW, Rezai Gharai L, et al. Cardiac MRI of hereditary cardiomyopathy[J]. Radiographics, 2022, 42(3):625-643.
2	Arbelo E, Protonotarios A, Gimeno JR, et al. ESC scientific document group. 2023 ESC Guidelines for the management of cardiomyopathies[J]. Eur Heart J, 2023, 44(37):3503-3626.
3	中华医学会医学遗传学分会遗传病临床实践指南撰写组. 遗传性心肌病的临床实践指南[J]. 中华医学遗传学杂志, 2020, 37(3):300-307.
4	McKenna WJ, Judge DP. Epidemiology of the inherited cardiomyopathies[J]. Nat Rev Cardiol, 2021, 18(1):22-36.
5	马阳光, 张雅永, 孟明耀, 等. 诱导多能干细胞在遗传性心脏疾病模型中的应用与机制[J]. 中国组织工程研究, 2024, 28(25):4072-4078.
6	Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors[J]. Cell, 2007, 131(5):861-872.
7	Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells[J]. Science, 2007, 318(5858):1917-1920.
8	胡敏洁,王思贤,王永煜.人诱导多能干细胞及其在血管相关疾病模型中的应用[J/OL].中华细胞与干细胞杂志（电子版）, 2022, 12(3):167-175.
9	Zhao M, Nakada Y, Wei Y, et al. Cyclin D2 overexpression enhances the efficacy of human induced pluripotent stem cell-derived cardiomyocytes for myocardial repair in a swine model of myocardial infarction[J]. Circulation, 2021, 144(3):210-228.
10	Ulmer BM, Eschenhagen T. Human pluripotent stem cell-derived cardiomyocytes for studying energy metabolism[J]. Biochim Biophys Acta Mol Cell Res, 2020, 1867(3):118471.doi:10.1016/j.bbamcr.2019.04.001.
11	Lagomarsino VN, Pearse RV 2nd, Liu L, et al. Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors[J]. Neuron, 2021, 109(21):3402-3420.e9.
12	Mun SJ, Ryu JS, Lee MO, et al. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids[J]. J Hepatol, 2019, 71(5):970-985.
13	Suezawa T, Kanagaki S, Moriguchi K, et al. Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids[J]. Stem Cell Reports, 2021, 16(12):2973-2987.
14	Kondo T, Imamura K, Funayama M, et al. iPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid β combination for Alzheimer's disease[J]. Cell Rep, 2017, 21(8):2304-2312.
15	Okamoto R, Takayama K, Akita N, et al. Human iPS cell-based liver-like tissue engineering at extrahepatic sites in mice as a new cell therapy for hemophilia B[J]. Cell Transplant, 2018, 27(2):299-309.
16	Zhu D, Xie M, Gademann F, et al. Protective effects of human iPS-derived retinal pigmented epithelial cells on retinal degenerative disease[J]. Stem Cell Res Ther, 2020, 11(1):98. doi: 10.1186/s13287-020-01608-8.
17	Lorenzini M, Norrish G, Field E, et al. Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers[J]. J Am Coll Cardiol, 2020, 76(5):550-559.
18	Velicki L, Jakovljevic DG, Preveden A, et al. Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy[J]. BMC Cardiovasc Disord, 2020, 20(1):516. doi: 10.1186/s12872-020-01807-4.
19	Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy[J]. Circ Res, 2017, 121(7):749-770.
20	Glavaški M, Velicki L, Vučinić N. Hypertrophic cardiomyopathy: genetic foundations, outcomes, interconnections, and their modifiers[J]. Medicina (Kaunas), 2023, 59(8):1424. doi:10.3390/medicina59081424.
21	Huang H, Chen Y, Jin J, et al. CSRP3, p.Arg122 is responsible for hypertrophic cardiomyopathy in a Chinese family[J]. J Gene Med, 2022, 24(1):e3390. doi: 10.1002/jgm.3390.
22	Lan F, Lee AS, Liang P, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells[J]. Cell Stem Cell, 2013, 12(1):101-113.
23	Wu H, Yang H, Rhee JW, et al. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients[J]. Eur Heart J, 2019, 40(45):3685-3695.
24	Ramachandra CJA, Kp MMJ, Chua J, et al. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes[J]. Cardiovasc Res, 2022, 118(2):517-530.
25	Ben Jehuda R, Eisen B, Shemer Y, et al. CRISPR correction of the PRKAG2 gene mutation in the patient's induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities[J]. Heart Rhythm, 2018, 15(2):267-276.
26	Finocchiaro G, Merlo M, Sheikh N, et al. The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy[J]. Eur J Heart Fail, 2020, 22(7):1097-1107.
27	Peters S, Johnson R, Birch S, et al. Familial dilated cardiomyopathy[J]. Heart Lung Circ, 2020, 29(4):566-574.
28	Jordan E, Hershberger RE. Considering complexity in the genetic evaluation of dilated cardiomyopathy[J]. Heart, 2021, 107(2):106-112.
29	Ye L, Ni X, Zhao ZA, et al. The application of induced pluripotent stem cells in cardiac disease modeling and drug testing[J]. J Cardiovasc Transl Res, 2018, 11(5):366-374.
30	Wang Y, Lei W, Yang J, et al. The updated view on induced pluripotent stem cells for cardiovascular precision medicine[J]. Pflugers Arch, 2021, 473(7):1137-1149.
31	Sun N, Yazawa M, Liu J, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy[J]. Sci Transl Med, 2012, 4(130):130ra47. doi:10.1126/scitranslmed.3003552.
32	Wu H, Lee J, Vincent LG, et al. Epigenetic regulation of phosphodiesterases 2A and 3A underlies compromised β-adrenergic signaling in an iPSC model of dilated cardiomyopathy[J]. Cell Stem Cell, 2015, 17(1):89-100.
33	Dai Y, Amenov A, Ignatyeva N, et al. Troponin destabilization impairs sarcomere-cytoskeleton interactions in iPSC-derived cardiomyocytes from dilated cardiomyopathy patients[J]. Sci Rep, 2020, 10(1):209. doi: 10.1038/s41598-019-56597-3.
34	Singh DP, Patel H. Left Ventricular noncompaction cardiomyopathy[M]. 2022 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
35	Hirono K, Hata Y, Miyao N, et al. Increased burden of ion channel gene variants is related to distinct phenotypes in pediatric patients with left ventricular noncompaction[J]. Circ Genom Precis Med, 2020, 13(4):e002940. doi: 10.1161/CIRCGEN.119.002940.
36	Hirono K, Ichida F. Left ventricular noncompaction: a disorder with genotypic and phenotypic heterogeneity-a narrative review[J]. Cardiovasc Diagn Ther, 2022, 12(4):495-515.
37	van Waning JI, Caliskan K, Michels M, et al. Cardiac phenotypes, genetics, and risks in familial noncompaction cardiomyopathy[J]. J Am Coll Cardiol, 2019, 73(13):1601-1611.
38	Thareja SK, Anfinson M, Cavanaugh M, et al. Altered contractility, Ca²⁺ transients, and cell morphology seen in a patient-specific iPSC-CM model of Ebstein's anomaly with left ventricular noncompaction[J]. Am J Physiol Heart Circ Physiol, 2023, 325(1):H149-H162.
39	Korover N, Etzion S, Cherniak A,et al. Functional defects in hiPSC-derived cardiomyocytes from patients with a PLEKHM2-mutation associated with dilated cardiomyopathy and left ventricular non-compaction[J]. Biol Res, 2023, 56(1):34. doi: 10.1186/s40659-023-00442-5.
40	Kodo K, Ong SG, Jahanbani F, et al. iPSC-derived cardiomyocytes reveal abnormal TGF-β signalling in left ventricular non-compaction cardiomyopathy[J]. Nat Cell Biol, 2016, 18(10):1031-1042.
41	Bluemke DA, James CA, Riele A. risk stratification in arrhythmogenic right ventricular cardiomyopathy: not a one-size-fits-all strategy [J]. J Am Coll Cardiol, 2020, 75(22): 2766-2768.
42	Cho Y. Arrhythmogenic right ventricular cardiomyopathy[J]. J Arrhythm, 2018, 34(4):356-368.
43	Murray B, James CA. Genotype-phenotype correlates in arrhythmogenic cardiomyopathies[J]. Curr Cardiol Rep, 2022, 24(11):1557-1565.
44	Chen P, Xiao Y, Wang Y, et al. Intracellular calcium current disorder and disease phenotype in OBSCN mutant iPSC-based cardiomyocytes in arrhythmogenic right ventricular cardiomyopathy[J]. Theranostics, 2020, 10(24):11215-11229.
45	Akdis D, Saguner AM, Shah K, et al. Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome[J]. Eur Heart J, 2017, 38(19):1498-1508. .
46	Kim C, Wong J, Wen J, et al Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs[J]. Nature, 2013, 494(7435):105-110.
47	El-Battrawy I, Zhao Z, Lan H, et al. Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy[J]. Europace, 2018, 20(FI1):f46-f56.
48	Zhuang Q, Guo F, Fu L, et al. 1-Deoxynojirimycin promotes cardiac function and rescues mitochondrial cristae in mitochondrial hypertrophic cardiomyopathy[J]. J Clin Invest, 2023, 133(14):e164660. doi: 10.1172/JCI164660.
49	Sanbe A, Nelson D, Gulick J, et al. In vivo analysis of an essential myosin light chain mutation linked to familial hypertrophic cardiomyopathy[J]. Circ Res, 2000, 87(4):296-302.
50	Giacomelli E, Meraviglia V, Campostrini G, et al. Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease[J]. Cell Stem Cell, 2020, 26(6):862-879.e11.
51	Ito M, Nomura S, Morita H, et al. Trends and limitations in the assessment of the contractile properties of human induced pluripotent stem cell-derived cardiomyocytes from patients with dilated cardiomyopathy[J]. Front Cardiovasc Med, 2020, 7:154. doi: 10.3389/fcvm.2020.00154.
52	Li H, Huang M, Wang J, et al.A method for establishing the electrophysiological model of alcoholic cardiomyopathy[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2020, 45(4):386-394.
53	Nakamura K, Murry C. Function follows form-a review of cardiac cell therapy[J]. Circ J, 2019, 83(12):2399-2412.
54	高原, 盛伟, 黄国英. 多能干细胞在体外心脏模型构建研究中的应用[J/OL]. 中华细胞与干细胞杂志（电子版）, 2022, 12(5):314-318.
55	武玉康, 康九红. 多能干细胞在心脏发育和疾病研究中的应用[J/OL]. 中华细胞与干细胞杂志（电子版）, 2022, 12(6):378-382.

疾病名称	发表年份	亮点	参考文献
HCM	2013	探索MYH7基因（p.R663H）突变在HCM中的作用机制，基于hiPSC模型发现与对照组相比，HCM组具有细胞增大和收缩性心律失常及细胞内钙循环增多等表型。	[22]
	2019	HCM患者hiPSC-CMs表现出舒张功能受损，表现为舒张时间延长、舒张率降低和舒张肌节长度缩短以及舒张期钙超载等表型。	[23]
	2022	首次证明iPSC-CMs中存在功能性的MPO，且在HCM-CMs中上调，通过增加3-氯酪氨酸修饰的MYBPC3蛋白水平来降低MYBPC3磷酸化水平，进而损害HCM-CMs中的心肌细胞舒张动力学。	[24]
	2018	PRKAG2突变的HCM hiPSC-CMs表现出结构和功能异常。利用CRISPR矫正后消除了电生理异常、糖原累积和心肌细胞肥大等异常表型。	[25]
DCM	2012	首次建立了携带TNNT2突变的DCM-hiPSC疾病模型。	[31]
	2015	利用TNNT2突变患者的hiPSC-CMs表征了心肌细胞在体外分化和成熟过程中的特性，并发现β肾上腺素能信号通路传导功能在DCM hiPSC-CMs中被减弱。	[32]
	2020	利用TNNT2突变的hiPSC系，揭示了基因突变后破坏了肌钙蛋白与其他肌节蛋白的相互作用。	[33]
LVNC	2023	利用KLHL26突变患者衍生出hiPSC-CMs，细胞表现出内质网扩张和线粒体畸形，以及收缩率降低、钙瞬变等异常表型。	[38]
	2023	利用PLEKHM2突变患者衍生hiPSC-CMs，发现这些心肌细胞自噬活性水平较低。	[39]
	2016	构建TBX20突变的LVNC患者的hiPSC-CMs，发现TBX20突变后TGFβ信号转导异位激活，最终损害了心肌多层致密结构的形成。利用CRISPR技术矫正后，降低了TGFβ信号转导活性。	[40]
ARVC	2020	利用OBSCN突变的ARVC-hiPSC生成心肌细胞，表现出明显的脂质积累、多形性增加、不规则的Z带和L型钙电流增加。	[44]
	2020	利用PKP2-hiPSC-CMs模型再现了ARVC脂肪生成和细胞凋亡的表型，并发现加入睾酮后表型恶化，雌二醇处理后表型有所改善。	[45]
	2013	利用PKP2突变的ARVC患者hiPSC诱导为具有异常JUP蛋白核易位的心肌细胞，且脂肪生成、细胞凋亡、活性氧产生和脂肪酸氧化通量等方面均显著增加，PPARγ拮抗剂可减少脂肪生成，添加活性氧清除剂可减少心肌细胞凋亡。	[46]
	2018	利用DSG2突变的ARVC患者的hiPSC生成心肌细胞，表现出多离子通道功能障碍和异常的细胞电生理学，以及对肾上腺素能刺激的敏感性增强。	[47]

疾病名称	发表年份	亮点	参考文献
HCM	2013	探索MYH7基因（p.R663H）突变在HCM中的作用机制，基于hiPSC模型发现与对照组相比，HCM组具有细胞增大和收缩性心律失常及细胞内钙循环增多等表型。	[22]
	2019	HCM患者hiPSC-CMs表现出舒张功能受损，表现为舒张时间延长、舒张率降低和舒张肌节长度缩短以及舒张期钙超载等表型。	[23]
	2022	首次证明iPSC-CMs中存在功能性的MPO，且在HCM-CMs中上调，通过增加3-氯酪氨酸修饰的MYBPC3蛋白水平来降低MYBPC3磷酸化水平，进而损害HCM-CMs中的心肌细胞舒张动力学。	[24]
	2018	PRKAG2突变的HCM hiPSC-CMs表现出结构和功能异常。利用CRISPR矫正后消除了电生理异常、糖原累积和心肌细胞肥大等异常表型。	[25]
DCM	2012	首次建立了携带TNNT2突变的DCM-hiPSC疾病模型。	[31]
	2015	利用TNNT2突变患者的hiPSC-CMs表征了心肌细胞在体外分化和成熟过程中的特性，并发现β肾上腺素能信号通路传导功能在DCM hiPSC-CMs中被减弱。	[32]
	2020	利用TNNT2突变的hiPSC系，揭示了基因突变后破坏了肌钙蛋白与其他肌节蛋白的相互作用。	[33]
LVNC	2023	利用KLHL26突变患者衍生出hiPSC-CMs，细胞表现出内质网扩张和线粒体畸形，以及收缩率降低、钙瞬变等异常表型。	[38]
	2023	利用PLEKHM2突变患者衍生hiPSC-CMs，发现这些心肌细胞自噬活性水平较低。	[39]
	2016	构建TBX20突变的LVNC患者的hiPSC-CMs，发现TBX20突变后TGFβ信号转导异位激活，最终损害了心肌多层致密结构的形成。利用CRISPR技术矫正后，降低了TGFβ信号转导活性。	[40]
ARVC	2020	利用OBSCN突变的ARVC-hiPSC生成心肌细胞，表现出明显的脂质积累、多形性增加、不规则的Z带和L型钙电流增加。	[44]
	2020	利用PKP2-hiPSC-CMs模型再现了ARVC脂肪生成和细胞凋亡的表型，并发现加入睾酮后表型恶化，雌二醇处理后表型有所改善。	[45]
	2013	利用PKP2突变的ARVC患者hiPSC诱导为具有异常JUP蛋白核易位的心肌细胞，且脂肪生成、细胞凋亡、活性氧产生和脂肪酸氧化通量等方面均显著增加，PPARγ拮抗剂可减少脂肪生成，添加活性氧清除剂可减少心肌细胞凋亡。	[46]
	2018	利用DSG2突变的ARVC患者的hiPSC生成心肌细胞，表现出多离子通道功能障碍和异常的细胞电生理学，以及对肾上腺素能刺激的敏感性增强。	[47]

[1]	Dandan Chen, Xiaojing Ma, Juan Xia. Evaluation of right ventricular function in patients with hypertrophic cardiomyopathy by two-dimensional speckle tracking imaging [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(04): 417-423.
[2]	Yu Chen, Fang Feng, Lu Zhang, Jian Liu. Bioinformatics analysis to screen key pathogenic genes in septic cardiomyopathy [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2023, 16(04): 286-291.
[3]	Kunkun Qiang, Hong Luo. Current research status and prospect in diagnosis of children with Duchenne muscular dystrophy by high-frequency ultrasound and shear wave elasticity imaging [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(02): 162-167.
[4]	Chuanju Li, Linyue Liu, Mei Wang, Xin Li, Xianghui Han, Haiyong Jia. Progress on models of hepatitis B virus infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(06): 361-365.
[5]	Ling Lin, Pei Li, Wei Zhao. Research progress in the pathogenesis of taurodontism [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(02): 75-80.
[6]	Jun Wu, Lixuan Chen, Yang Xiao. Analysis of dual filing research projects on stem cells in China [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(05): 304-309.
[7]	Jiaming Fan, Ziying Yang, Zhenhui Feng, Yihuan Chen, Yutong Wang, Zhenya Shen. Analysis of differential miRNA expression related to the efficacy of stem cell transplantation in dilated cardiomyopathy [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(05): 288-298.
[8]	Ke Fang, Huanhuan Da, Jun Wang, Ruixiang Sun, Tao Wang, Yang Li, Haijiao Jiang, Weihua Lu. ECMO assisted adrenal excision for pheochromocytoma catecholamine cardiomyopathy during pregnancy: a case report and literature review [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2023, 09(03): 304-310.
[9]	Xiaoxiao Liu, Xiaoshan Zhang, Qun Liu, Lan Ma, Haiyue Zhao, Yaxi Wang. Progress in application of echocardiography in perinatal cardiomyopathy [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(11): 1196-1201.
[10]	Chuanwei Li, Qian Wen, Hao Luo. Long-term clinical efficacy and safety of coil embolization of the septal perforator in patients with hypertrophic obstructive cardiomyopathy [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(01): 68-71.
[11]	Zhen Teng, Bo Yan. Research progress of transcription factor HAND1 gene polymorphism in cardiovascular disease [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(01): 5-11.
[12]	Qi Lu, Chuanfang Li, Lijun Gan. Advances in molecular mechanisms of alcoholic cardiomyopathy [J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(04): 248-252.
[13]	Xinyi Xu, Yijing Gu, Ying Guo, Xiuli Wang, Meirong Huang, Lijun Fu, Wei Gao, Tingliang Liu, Fen Li. Clinical management and prognosis analysis of pediatric tachycardia-induced cardiomyopathy [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2023, 11(04): 216-221.
[14]	Yang Hua, Jinyu Sun, Chen Cheng, Ziling Xin, Yanhui Sheng, Xiangqing Kong, Wei Sun. Identification of key genes and pathways in hypertrophic cardiomyopathy via weighted gene co-expression network analysis [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2023, 11(01): 32-38.
[15]	Ying Li, Xueliang Qi, Liqun Feng, Tong Liu, Guangzhi Liu. Research progress in diagnosis and treatment of cardiomyopathy-related ischemic stroke [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2022, 16(05): 356-359.

Please choose a citation manager

Content to export